# DESCRIPTION

## BACKGROUND OF THE DISCLOSURE

- introduce Rett syndrome
- motivate research for cure

## BRIEF SUMMARY OF THE DISCLOSURE

- introduce SEMA4D binding molecules
- describe method for improving symptoms
- describe method of treating Rett syndrome
- specify binding molecule properties
- describe receptor options
- describe signal transduction inhibition
- specify epitope binding
- describe competitive inhibition
- specify antibody or antigen-binding fragment
- describe variable chain compositions

## DETAILED DESCRIPTION OF THE DISCLOSURE

### I. Definitions

- define "a" or "an" entity
- define "and/or"
- define technical and scientific terms
- define units, prefixes, and symbols
- define numeric ranges
- define amino acid sequences
- define headings
- define "non-naturally occurring" substance
- define "neurodevelopmental disorder"
- define "Rett syndrome"
- define "therapeutically effective amount"
- define "symptoms"
- define "treating" or "treatment"
- define "subject" or "individual"
- define "binding molecule"
- define "antigen binding molecule"
- define "anti-SEMA4D antibody"
- define "human" or "fully human" antibodies
- define "human" or "fully human" antibodies with variants
- define "immunoglobulin"
- define "antibody"
- define "heavy chain"
- define "light chain"
- define "variable domain"
- define "constant domain"
- define "complementarity determining regions" (CDRs)
- define "framework regions"
- define "antigen binding domain"
- define "epitope"
- define "immunoreactive antigen"
- define "CDRs" by Kabat et al.
- define "CDRs" by Chothia and Lesk
- define SEMA4D
- define SEMA4D expression
- define SEMA4D function
- define SEMA4D in neurodevelopmental disorders
- define SEMA4D in autoimmune diseases
- define SEMA4D in demyelinating diseases
- define SEMA4D in certain cancers
- define "subject that would benefit from administration of an anti-SEMA4D antibody"
- define "animal in need of treatment"
- define "method of alleviating symptoms in a subject having Rett syndrome"
- define "administering to the subject an anti-SEMA4D binding molecule"
- define Kabat numbering system
- specify antibody or antigen-binding fragments, variants, or derivatives
- describe heavy chain portion
- specify light chain portion
- define epitope
- describe minimum size of peptide or polypeptide epitope
- define specifically binds
- define preferentially binds
- describe competitive inhibition
- define affinity
- define avidity
- describe cross-reactivity
- specify binding affinity to polypeptide
- define chimeric antibody
- define engineered antibody
- describe humanized antibody
- specify framework regions
- describe human framework regions
- describe partially human framework regions
- specify humanized antibody residues
- define healthcare provider
- define healthcare benefits provider
- define clinical laboratory
- describe antibody or antigen-binding fragments, variants, or derivatives
- specify heavy chain portion
- specify light chain portion
- describe epitope
- describe minimum size of peptide or polypeptide epitope
- define specifically binds
- define preferentially binds
- describe competitive inhibition
- define affinity
- define avidity
- describe cross-reactivity
- specify binding affinity to polypeptide
- define chimeric antibody
- define engineered antibody
- describe humanized antibody
- specify framework regions
- describe human framework regions
- describe partially human framework regions
- specify humanized antibody residues
- summarize definitions

### II. Target Polypeptide Description

- define SEMA4D
- describe SEMA4D structure
- introduce SEMA4D isoforms
- describe SEMA4D receptors
- introduce Plexin-B1 receptor
- describe Plexin-B1 signaling
- introduce Plexin-B2 receptor
- describe Plexin-B2 function
- introduce CD72 receptor
- describe CD72 function
- summarize SEMA4D effects on immune cells
- describe SEMA4D expression pattern
- introduce SEMA4D knockout mice
- describe SEMA4D knockout mouse phenotype
- introduce soluble SEMA4D in autoimmune diseases
- describe SEMA4D in demyelinating diseases
- introduce SEMA4D upregulation in neurodegenerative diseases
- describe SEMA4D blocking therapy

### III. Anti-SEMA4D Antibodies

- introduce anti-SEMA4D antibodies
- reference prior art
- describe method of alleviating Rett syndrome symptoms
- specify antibody properties
- list exemplary antibodies
- describe antibody fragments, variants, and derivatives
- specify antibody binding properties
- describe antibody sequence identity
- specify VH domain properties
- describe CDR sequence identity
- specify VL domain properties
- describe VL domain sequence identity
- specify antibody variants with conservative substitutions
- describe polynucleotides encoding antibodies
- specify vectors and host cells
- describe biologically active antibody variants
- specify methods for making antibody variants
- describe mutagenesis and nucleotide sequence alterations
- specify guidance for conservative amino acid substitutions
- describe constructing antibody variants
- specify methods for measuring antibody binding specificity
- describe competitive binding assays
- specify T cell proliferation assays
- describe apoptosis assays
- specify ELISA assays
- describe percentage sequence identity
- specify Smith-Waterman homology search algorithm
- describe BLOSUM matrix
- specify gap open and extension penalties
- describe percentage of sequence identity
- specify optimal alignment
- describe BLAST 2 Sequences program
- specify default parameters
- describe constant region mutations
- specify Fc receptor binding
- describe effector function modifications
- specify antibody derivatives
- describe covalent attachment of molecules
- specify chemical modifications
- describe conservative amino acid substitutions
- specify saturation mutagenesis
- describe screening for biological activity
- specify optimizing codon usage

### IV. MeCP2

- introduce MeCP2 protein
- describe MeCP2 function in brain
- explain MeCP2 mutations and Rett syndrome

### V. Characteristic Symptoms of Rett Syndrome

- describe Stage I of Rett syndrome
- describe Stage II of Rett syndrome
- describe Stage III of Rett syndrome
- describe Stage IV of Rett syndrome
- compare Rett syndrome patients and MeCP2-deficient mice
- summarize symptoms of Rett syndrome

### VI. Astrocytes

- introduce astrocytes and their functions
- describe MeCP2 expression in astrocytes
- explain astrocyte contribution to Rett syndrome
- describe impaired astrocyte function in Rett syndrome
- discuss need for new molecular targets
- describe global re-expression of MeCP2 in mice
- explain astrocytic MeCP2 support of neuronal morphology
- describe MeCP2 regulation of astrocyte gene promoters
- explain rapid astrogenesis in Rett syndrome
- describe impact of astrocytes on neurons in disease
- summarize astrocyte role in Rett syndrome

### VII. Treatment Methods Using Therapeutic Anti-SEMA4D Antibodies

- introduce anti-SEMA4D binding molecules
- describe treatment of Rett syndrome with anti-SEMA4D antibodies
- explain SEMA4D receptor expression
- describe Plexin-B1 receptor
- introduce anti-SEMA4D antibody administration
- describe pharmaceutical composition of anti-SEMA4D antibodies
- explain treatment goals for Rett syndrome
- describe improvement of symptoms
- describe reduction of symptoms
- describe prevention of symptoms
- introduce use of anti-SEMA4D binding molecules as medicament
- describe positive therapeutic response
- discuss in vivo mouse models for Rett syndrome

### VIII. Pharmaceutical Compositions and Administration Methods

- introduce pharmaceutical compositions
- describe administration methods
- discuss route of administration
- define parenteral administration
- list pharmaceutical composition components
- describe buffer composition
- describe surfactant composition
- describe stabilizer agent composition
- discuss delivery methods
- describe pharmaceutically effective amount
- define pharmaceutical composition components
- list carrier materials
- describe ion exchangers
- describe alumina
- describe aluminum stearate
- describe lecithin
- describe serum proteins
- describe buffer substances
- describe partial glyceride mixtures
- describe water and salts
- describe colloidal silica
- describe magnesium trisilicate
- describe polyvinyl pyrrolidone
- describe cellulose-based substances
- describe polyethylene glycol
- describe sodium carboxymethylcellulose
- describe polyacrylates
- describe waxes
- describe polyethylene-polyoxypropylene-block polymers
- describe preparations for parenteral administration
- describe sterile aqueous or non-aqueous solutions
- describe suspensions and emulsions
- describe pharmaceutical composition processing
- describe packaging and labeling
- discuss parenteral formulations
- describe oral administration
- describe nasal aerosol or inhalation administration
- discuss therapeutically effective dose or amount

## EXAMPLES

### Example 1: Testing the Effects of an Anti-SEMA4D Binding Molecule on Symptoms Associated with Rett Syndrome in the Mecp2T158A Rett Syndrome Mouse Model

- introduce experimental design
- describe mouse model creation
- outline preclinical trial design
- describe treatment protocol
- outline phenotypic scoring
- describe rotarod test
- describe elevated plus maze test
- describe whole body plethysmography test
- outline statistical analysis
- analyze hindlimb clasping in pre-symptomatic mice
- analyze body tremors in pre-symptomatic mice
- analyze coordination and locomotion in pre-symptomatic mice
- analyze cognition in pre-symptomatic mice
- analyze respiratory pattern in pre-symptomatic mice
- analyze hindlimb clasping in symptomatic mice
- analyze body tremors in symptomatic mice
- analyze coordination and locomotion in symptomatic mice
- analyze cognition in symptomatic mice
- analyze respiratory pattern in symptomatic mice
- summarize results of studies
- describe SEMA4D upregulation in Rett mice
- describe immunohistochemistry staining
- describe SEMA4D antibody
- describe neuronal marker HuC/HuD
- show representative images of hippocampus regions
- compare SEMA4D expression in Rett mice and wild type controls
- compare HuC/HuD expression in Rett mice and wild type controls
- discuss SEMA4D upregulation in Rett mice
- discuss implications of SEMA4D upregulation
- discuss potential therapeutic applications
- conclude SEMA4D upregulation in Rett mice

